Safety and feasibility of pancreas resection after a-smart in pancreatic cancer:Multicenter analysis

Background: Neoadjuvant chemotherapy coupled with radiotherapy (RT) may provide survival benefits when compared to upfront surgery in patients with borderline resectable pancreatic cancer. It is hypothesized that delivering precise, ablative doses of radiation allows for improved outcomes without increasing significant treatment-related toxicity. The purpose of the present study is to evaluate the safety and feasibility of surgical resection after neoadjuvant ablative stereotactic magnetic resonance-guided adaptive radiation therapy (A-SMART) in patients with pancreatic cancer.